Latest period
$380M
YoY change
+33.0%
5Y CAGR
+12.5%
Peak year (FY2021)
$485M
Latest annual
$343M
Cash on Hand history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: $343M
Cash on Hand growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: +33.0%
Cash on Hand history table for Tango Therapeutics (TNGX) from 2019 to 2025
| FY2025 | $343M | +33.0% | +$85.2M | ||
| FY2024 | $258M | -23.4% | -$79M | ||
| FY2023 | $337M | -8.0% | -$29.2M | ||
| FY2022 | $366M | -24.5% | -$119M | ||
| FY2021 | $485M | +155.0% | +$295M | ||
| FY2020 | $190M | +370.8% | +$150M | ||
| FY2019 | $40.4M | — | — |
- FY2025$343M+33.0%
- FY2024$258M-23.4%
- FY2023$337M-8.0%
- FY2022$366M-24.5%
- FY2021$485M+155.0%
- FY2020$190M+370.8%
- FY2019$40.4M—
Cash on Hand values are taken from Tango Therapeutics's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's latest reported cash and short-term investments is $380M. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Tango Therapeutics (TNGX) reported cash and short-term investments of $343M – surged 33.0% year-over-year.
Over 2020–2025 (5 years), Tango Therapeutics cash and short-term investments expanded at a +12.5% compound annual rate, with mixed annual results across the window.
Tango Therapeutics cash and short-term investments declined from $485M in 2021 to $343M in 2025, a 29.3% drawdown.
$485M stands as the all-time-high annual cash and short-term investments, posted in 2021, against a low of $40.4M during 2019.
Tango Therapeutics Cash on Hand by Year
Tango Therapeutics Cash on Hand 2025: $343M
Tango Therapeutics cash and short-term investments in 2025 was $343M, surged 33.0% from 2024.
Tango Therapeutics Cash on Hand 2024: $258M
2024's cash and short-term investments for Tango Therapeutics came in at $258M, declined 23.4% below 2023.
Tango Therapeutics Cash on Hand 2023: $337M
Tango Therapeutics posted cash and short-term investments of $337M in 2023, declined 8.0% below 2022.
Tango Therapeutics Cash on Hand 2022: $366M
In 2022, Tango Therapeutics reported cash and short-term investments of $366M, declined 24.5% below 2021.
Tango Therapeutics Cash on Hand 2021: $485M
Tango Therapeutics cash and short-term investments in 2021 was $485M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by Cash on Hand
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest cash and short-term investments
| $28.1B | |
| $20.1B | |
| $14.6B | |
| $10.1B | |
| $9.13B | |
| $7.27B | |
| $5.26B | |
| $4.24B |
- $28.1B
- $20.1B
- $14.6B
- $9.13B
- $7.27B
- $5.26B
- $4.24B
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.